This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Marchlinski, F. E. Search for Related Content PubMed PubMed Citation Articles by Marchlinski, F. E. Related Collections Arrhythmias, clinical electrophysiology, drugs Ablation/ICD/surgery Related Article

Editorials

Ventricular Tachycardia Ablation

Moving Beyond Treatment of Last Resort

Francis E. Marchlinski, MD

From the Cardiovascular Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Penn.

Correspondence to Francis E. Marchlinski, MD, Hospital of the University of Pennsylvania, Department of Medicine, Division of Cardiology, 9 Founders Pavilion, 3400 Spruce St, Philadelphia, PA 19104. E-mail francis.marchlinski@uphs.upenn.edu

Key Words: ablation • arrhythmia • tachycardia • ventricles

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The use of ventricular tachycardia (VT) ablation in patients with structural heart disease remains reserved primarily for those who experience repeated implantable cardioverter defibrillator shocks despite pharmacological and attempted pacing therapy. This fact is confirmed by the comprehensive 8-year report of the experience with VT ablation by the group from the Brigham and Womens’ Hospital.¹ Even at this very experienced center, most patients with VT in the setting of structural heart disease who were referred for catheter ablation had an implantable cardioverter defibrillator (80%), and most patients (75%) were experiencing recurrent shocks in the week before ablation, with VT storm in 30%. The group with structural heart disease failed a mean of 3 antiarrhythmic drugs, and the overwhelming majority of patients—84% in the ischemic cardiomyopathy group and 59% in the nonischemic cardiomyopathy (NICM) group—were treated with amiodarone. This tendency to "hold back" on catheter ablation therapy for VT seems to be even more dramatic as a current practice standard than previously noted. In our own institutional experience, when comparing the clinical characteristics of consecutive patients referred for VT ablation with coronary disease over a comparable time period from the mid-1990s with the current decade (Table), we observed a significant increase in the use of implantable cardioverter defibrillator therapy and amiodarone before ablation.² Patients also appear to have poorer left ventricular function as indexed by a decline in left ventricular ejection fraction.

View this table:   Table. Comparison of Patient Characteristics Undergoing VT Ablation

 

Article see p 153

It is important to determine . . . [Full Text of this Article]

Related Article

Ventricular Tachycardia Ablation: Evolution of Patients and Procedures Over 8 Years

Frédéric Sacher, Usha B. Tedrow, Michael E. Field, Jean-Marc Raymond, Bruce A. Koplan, Laurence M. Epstein, and William G. Stevenson
Circ Arrhythm Electrophysiol 2008 1: 153-161. [Abstract] [Full Text] [PDF]